Table 2.

Characteristics of patients with confirmed or suspected COVID-19 and MS or NMOSD.

Patient	RT-PCR	Sex	Age (years)	Diagnosis	Disease Duration (years)	EDSS	Comorbidities	DMT	DMT modification or interruption	Hospitalization	IMV	COVID-19 symptoms and Follow-up	Outcome
1	positive	male	30	RRMS	6	1	insulin resistance, hypothyroidism	ocrelizumab	no change - last infusion 10 days before symptoms onset	yes	no	bilateral pneumonia, readmission due to Adenovirus pneumonia	full recovery
2	positive	female	23	RRMS	8	1	insulin resistance	dimethyl fumarate	suspended for 35 days until clinical recovery	yes	no	bilateral pneumonia	full recovery
3	positive	female	24	RRMS	9	1	migraine, depression, insulin resistance	fingolimod	suspended for 21 days until clinical recovery	yes	no	myalgias and fever	full recovery
4	positive	male	61	NMOSD-AQP4	0.3	6	hypertension, type 2 diabetes	prednisone	steroid stress dose	yes	yes	bilateral pneumonia, tracheostomy	fatal
5	positive	female	54	NMOSD-AQP4	12	3	insulin resistance, pernicious anemia, osteoarthritis	mycophenolate	no change	no	no	anosmia	full recovery
6	positive	female	29	RRMS	7	1	hypothyroidism	fingolimod	suspended for 5 days until clinical recovery	no	no	myalgias and fever	full recovery
7	not performed - close contact with positive PCR, positive IgM	female	23	RRMS	2.5	1	obesity	dimethyl fumarate	no change	no	no	myalgias and fever	full recovery
8	positive	male	55	RRMS	7	1	depression	teriflunomide	suspended for 7 days until clinical recovery	no	no	myalgias and fever, recovering at home	full recovery
9	positive	female	57	RRMS	7	4	anxiety, type 2 diabetes	fingolimod	no change	no	no	sore throat, headache, mild dyspnea	full recovery
10	positive	male	17	RRMS	2	0	asthma	fingolimod	no change	no	no	asymptomatic	full recovery
11	not performed - close contact with positive PCR	female	28	NMOSD	3	2.5	obesity	mycophenolate	no change	no	no	anosmia, fever and diarrhea	full recovery
12	not performed - close contact with positive PCR, positive IgG	female	44	RRMS	6	3	depression, cutaneous amyloidosis	natalizumab	last dose 4 months prior infection - waiting for switching to cladribine	no	no	anosmia, diarrhea, fever	full recovery
13	positive	male	40	NMOSD-MOG	0.6	2.5	depression	azathioprine	suspension for 1 month	yes	no	myalgia, fever and sore throat, dyspnea, suspected bacterial sobreinfection, received tocilizumab	full recovery
14	positive	female	52	RRMS	8	1	depression, obesity, hypertension, insulin resistance	teriflunomide	no change	no	no	dry cough	full recovery
15	positive	female	31	RRMS	3	2	hypothyroidism	fingolimod	no change	no	no	asymptomatic	full recovery
16	positive, IgG positive	female	34	RRMS	7	1	secondary thyroiditis	alemtuzumab	no change - last dose October 2018	no	no	myalgia, headache, anosmia	recovering at home
17	positive	male	36	RRMS	4	2	migraine, depression	interferon beta 1a IM	no change	no	no	myalgia, rhinorrhea, anosmia	recovering at home
18	not performed, negative IgG	female	31	RRMS	14	1	migraine	alemtuzumab 4 doses, ocrelizumab	no change - last infusion 2 months before symptom onset	no	no	fever, myalgia, headache, anosmia	recovering at home

RT-PCR: real-time polymerase chain reaction; RRMS relapsing-remitting multiple sclerosis; NMOSD Neuromyelitis Optica Spectrum Disorder; AQP4 aquaporin 4; MOG myelin oligodendrocyte glycoprotein; EDSS expanded disability status scale, DMT disease modifying therapy, IMV invasive mechanical ventilation.